Filing Details
- Accession Number:
- 0001567619-19-019579
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-15 18:24:16
- Reporting Period:
- 2019-10-10
- Accepted Time:
- 2019-10-15 18:24:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
827871 | Eagle Pharmaceuticals Inc. | EGRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1495110 | L Douglas Braunstein | 570 Lexington Avenue, 35Th Floor New York NY 10022 | Yes | No | No | No | |
1652522 | Hudson Executive Capital Lp | 570 Lexington Avenue 35Th Floor New York NY 10022 | Yes | No | No | No | |
1700567 | Hec Management Gp Llc | 570 Lexington Avenue 35Th Floor New York NY 10022 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2019-10-10 | 7,829 | $60.16 | 796,077 | No | 4 | S | Indirect | See footnotes |
Common Stock | Disposition | 2019-10-11 | 16,300 | $60.39 | 779,777 | No | 4 | S | Indirect | See footnotes |
Common Stock | Disposition | 2019-10-15 | 3,909 | $62.63 | 775,868 | No | 4 | S | Indirect | See footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnotes |
No | 4 | S | Indirect | See footnotes |
No | 4 | S | Indirect | See footnotes |
Footnotes
- The sale of shares set forth herein is made pursuant to a sales plan under Rule 10b5-1(c).
- The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.0000 to $60.4900, inclusive. The Reporting Persons (defined below) undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- In addition to Hudson Executive Capital LP, a Delaware limited liability company ("Hudson Executive"), this Form 4 is being filed jointly by HEC Management GP LLC, a Delaware limited liability company ("Management GP"), and Douglas L. Braunstein, a citizen of the United States of America (together with Hudson Executive and Management GP, the "Reporting Persons"), each of whom has the same business address as Hudson Executive and may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the "Subject Securities").
- Hudson Executive, as the investment adviser to certain affiliated investment funds, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934. Management GP, as the general partner of Hudson Executive, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a). By virtue of Mr. Braunstein's position as Managing Partner of Hudson Executive and Managing Member of Management GP, Mr. Braunstein may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) and Hudson Executive and Management GP may be deemed to be the beneficial owner of the Subject Securities held by Mr. Braunstein.
- Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $60.0000 to $61.1200, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $62.5000 to $62.9300, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.